Contents

Search

homotaurine; 3-Amino-1-propanesulfonic acid; tramiprosate; ALZ-801

Indications: - phase 3 clinical trials for Alzheimer's disease - may be most useful for patients with 2 apoE4 alleles - of no benefit for patients without apoE4 alleles [1] Dosage: - 150 mg BID Mechanism of action: - blocks aggregation of beta-amyloid monomers into toxic oligomers - gene-dose effect for APOE4 carriers [1]

General

pharmaceutical agents for treatment of Alzheimer's disease (Alzheimer's agent) amine sulfonic acid

Database Correlations

PUBCHEM correlations

References

  1. EurekAlert. Oct 24, 2016 Phase 3 analyses in Alzheimer's show clinical benefit of tramiprosate in APOE4 carriers https://www.eurekalert.org/pub_releases/2016-10/tyn-p3102416.php